123 related articles for article (PubMed ID: 2138080)
21. Striatal dopamine D2 receptor alterations and response to L-DOPA in Parkinson's disease. A [123I]IBZM SPET study.
Pizzolato G; Cagnin A; Rossato A; Chierichetti F; Fabbri M; Dam M; Ferlin G; Battistin L
Adv Neurol; 1996; 69():467-73. PubMed ID: 8615167
[No Abstract] [Full Text] [Related]
22. Differential involvement of D1 and D2 dopamine receptors in L-DOPA-induced angiogenic activity in a rat model of Parkinson's disease.
Lindgren HS; Ohlin KE; Cenci MA
Neuropsychopharmacology; 2009 Nov; 34(12):2477-88. PubMed ID: 19606087
[TBL] [Abstract][Full Text] [Related]
23. 3H-Flupenthixol binding in post-mortem brains of schizophrenics: evidence for a selective increase in dopamine D2 receptors.
Cross AJ; Crow TJ; Owen F
Psychopharmacology (Berl); 1981; 74(2):122-4. PubMed ID: 6791218
[TBL] [Abstract][Full Text] [Related]
24. Dopamine receptors--the present state of research and perspectives.
Wolfarth S; Ossowska K
Pol J Pharmacol; 1995; 47(3):207-18. PubMed ID: 8714754
[TBL] [Abstract][Full Text] [Related]
25. Dopamine D2 receptor density in parkinsonian brain is constant for duration of disease, age, and duration of L-dopa therapy.
Guttman M; Seeman P
Adv Neurol; 1987; 45():51-7. PubMed ID: 2950731
[No Abstract] [Full Text] [Related]
26. [3H] GBR 12935 binding to the dopamine uptake site in post-mortem brain tissue in schizophrenia.
Czudek C; Reynolds GP
J Neural Transm; 1989; 77(2-3):227-30. PubMed ID: 2760605
[TBL] [Abstract][Full Text] [Related]
27. Effects of single and multiple treatments with L-dihydroxyphenylalanine (L-DOPA) on dopamine receptor-G protein interactions and supersensitive immediate early gene responses in striata of rats after reserpine treatment or with unilateral nigrostriatal lesions.
Khan SM; Smith TS; Bennett JP
J Neurosci Res; 1999 Jan; 55(1):71-9. PubMed ID: 9890435
[TBL] [Abstract][Full Text] [Related]
28. Imaging of dopamine D1 and D2 receptors by a high resolution positron emission tomography.
Shinotoh H; Aotsuka A; Inoue O; Suzuki K; Fukuda H; Iyo M; Yamazaki T; Tateno Y; Hirayama K; Nohara N
Adv Exp Med Biol; 1991; 287():249-53. PubMed ID: 1836930
[No Abstract] [Full Text] [Related]
29. Dopaminergic functional supersensitivity: effects of chronic L-dopa and carbidopa treatment in an animal model of Parkinson's disease.
Hossain MA; Weiner N
J Pharmacol Exp Ther; 1993 Dec; 267(3):1105-11. PubMed ID: 8263772
[TBL] [Abstract][Full Text] [Related]
30. Effect of the putative dopamine D1 agonist and D2 antagonist FCE 23884 on Parkinson's disease.
Metman LV; Blanchet PJ; de Jong D; Mouradian MM; Chase TN
Mov Disord; 1996 May; 11(3):257-60. PubMed ID: 8723141
[TBL] [Abstract][Full Text] [Related]
31. Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL-PET study.
Whone AL; Watts RL; Stoessl AJ; Davis M; Reske S; Nahmias C; Lang AE; Rascol O; Ribeiro MJ; Remy P; Poewe WH; Hauser RA; Brooks DJ;
Ann Neurol; 2003 Jul; 54(1):93-101. PubMed ID: 12838524
[TBL] [Abstract][Full Text] [Related]
32. Human post-mortem striatal alpha4beta2 nicotinic acetylcholine receptor density in schizophrenia and Parkinson's syndrome.
Durany N; Zöchling R; Boissl KW; Paulus W; Ransmayr G; Tatschner T; Danielczyk W; Jellinger K; Deckert J; Riederer P
Neurosci Lett; 2000 Jun; 287(2):109-12. PubMed ID: 10854724
[TBL] [Abstract][Full Text] [Related]
33. Dopamine receptor SPET imaging in Parkinson's disease: a [123I]-IBZM and [99mTc]-HM-PAO study.
Pizzolato G; Chierichetti F; Rossato A; Briani C; Dam M; Borsato N; Saitta B; Zanco P; Ferlin G; Battistin L
Eur Neurol; 1993; 33(2):143-8. PubMed ID: 8467821
[TBL] [Abstract][Full Text] [Related]
34. Altropane, a SPECT or PET imaging probe for dopamine neurons: III. Human dopamine transporter in postmortem normal and Parkinson's diseased brain.
Madras BK; Gracz LM; Fahey MA; Elmaleh D; Meltzer PC; Liang AY; Stopa EG; Babich J; Fischman AJ
Synapse; 1998 Jun; 29(2):116-27. PubMed ID: 9593102
[TBL] [Abstract][Full Text] [Related]
35. Glutamate/dopamine D1/D2 balance in the basal ganglia and its relevance to Parkinson's disease.
Starr MS
Synapse; 1995 Apr; 19(4):264-93. PubMed ID: 7792721
[TBL] [Abstract][Full Text] [Related]
36. Dopamine receptors in the basal ganglia: relevance to Parkinson's disease.
Strange PG
Mov Disord; 1993 Jul; 8(3):263-70. PubMed ID: 8101967
[TBL] [Abstract][Full Text] [Related]
37. Dopaminergic agonists in the treatment of Parkinson's disease: a review.
Piccoli F; Riuggeri RM
J Neural Transm Suppl; 1995; 45():187-95. PubMed ID: 8748625
[TBL] [Abstract][Full Text] [Related]
38. Alterations of striatal dopamine D2 receptors contribute to deteriorated response to L-dopa in Parkinson's disease: a [123I]-IBZM SPET study.
Pizzolato G; Chierichetti F; Rossato A; Cagnin A; Fabbri M; Dam M; Ferlin G; Battistin L
J Neural Transm Suppl; 1995; 45():113-22. PubMed ID: 8748616
[TBL] [Abstract][Full Text] [Related]
39. Damage to dopamine systems differs between Parkinson's disease and Alzheimer's disease with parkinsonism.
Murray AM; Weihmueller FB; Marshall JF; Hurtig HI; Gottleib GL; Joyce JN
Ann Neurol; 1995 Mar; 37(3):300-12. PubMed ID: 7695230
[TBL] [Abstract][Full Text] [Related]
40. Task-dependent interactions between dopamine D2 receptor polymorphisms and L-DOPA in patients with Parkinson's disease.
Kwak Y; Bohnen NI; Müller ML; Dayalu P; Burke DT; Seidler RD
Behav Brain Res; 2013 May; 245():128-36. PubMed ID: 23439215
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
